>>Signaling Pathways>> MAPK Signaling>> p38>>Anti-inflammatory agent 35

Anti-inflammatory agent 35

Catalog No.GC68671

항염증제 35 (화합물 5a27)은 구강 투여로 유효한 우슬초 추출물과 비슷한 화합물로, 항염작용을 가지고 있습니다. 항염증제 35는 세포분열활성화단백질키나아제(MAPK) 신호와 NF-kB의 핵 이동을 차단할 수 있습니다. 또한, 항염증제 35는 엽록체 침윤 및 염증 촉진 세포인자 생성을 억제합니다. 체내 연구에서, 항염증제 35는 지질 다당체(LPS) 유도 급성 폐손상(ALI)을 유의하게 완화시켰습니다.

Products are for research use only. Not for human use. We do not sell to patients.

Anti-inflammatory agent 35 Chemical Structure

Cas No.: 2293951-00-3

Size 가격 재고 수량
10mg
US$108.00
재고 있음
25mg
US$225.00
재고 있음
50mg
US$364.50
재고 있음
100mg
US$585.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Chemical Properties of Anti-inflammatory agent 35

Cas No. 2293951-00-3 SDF
Formula C27H29NO8 M.Wt 495.52
Solubility DMSO : 16.67 mg/mL (33.64 mM; ultrasonic and warming and heat to 60°C) Storage 4°C, protect from light
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Anti-inflammatory agent 35

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.0181 mL 10.0904 mL 20.1808 mL
5 mM 0.4036 mL 2.0181 mL 4.0362 mL
10 mM 0.2018 mL 1.009 mL 2.0181 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of Anti-inflammatory agent 35

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

리뷰

Review for Anti-inflammatory agent 35

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Anti-inflammatory agent 35

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.